MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1210/clinem/dgag140

Медицинская библиотека · The Journal of clinical endocrinology and metabolism · 2026

Real-world effectiveness of burosumab across age groups: X-linked hypophosphatemia (XLH) Disease Monitoring Program.

Ward Leanne M, Carpenter Thomas O, Cassinelli Hamilton, Florenzano Pablo, Imel Erik A, Khan Aliya A, Johnson Ben, Yang Erru, Vincent Marc, Heerssen Heather M, Li Zhiyi, Simmons Jill H

СтатьяПеревод в очереди

Аннотация

CONTEXT: X-linked hypophosphatemia (XLH) is a rare disorder characterized by excess fibroblast growth factor 23 (FGF23), leading to chronic hypophosphatemia, osteomalacia, and rickets.

OBJECTIVE

To evaluate outcomes up to 3 years following initiation of treatment with anti-FGF23 antibody (burosumab) in a real-world setting among individuals with XLH, stratified by age group, including those excluded from clinical trials (<1, 13-17, and ≥65 years).

METHODS

The XLH Disease Monitoring Program is a prospective, longitudinal, long-term-outcomes program for individuals with XLH. This analysis included participants who were burosumab-naive at baseline and who had initiated burosumab between baseline and the Year 1 visit. Changes from baseline in biochemistry, clinical outcomes, and patient-reported outcomes (PROs) were assessed at Year 1 (Y1) and Year 3 (Y3) visits.

RESULTS

Among participants (n = 139), burosumab led to significant and sustained improvements in mean (SD) serum phosphate z-scores at Y1 and Y3 (change from baseline: 1.4 [1.1]; P < .0001 for each timepoint). Among pediatric participants, serum alkaline phosphatase z-scores, Rickets Severity Scores, and patient-reported pain interference declined significantly at Y1 and Y3; non-significant changes were observed in fatigue and physical function mobility. Adults showed significant improvements in PRO measures of pain, stiffness, and physical function, with higher proportions of participants achieving minimal clinically important differences at Y3 vs Y1. Trends observed in overall cohorts were generally consistent across age sub-groups, with statistical significance reached for many endpoints.

CONCLUSION

This analysis demonstrated the real-world effectiveness of burosumab for XLH, which appears evident across age groups.

Для цитирования: Ward Leanne M, Carpenter Thomas O, Cassinelli Hamilton, Florenzano Pablo, Imel Erik A, Khan Aliya A, Johnson Ben, Yang Erru, Vincent Marc, Heerssen Heather M, Li Zhiyi, Simmons Jill H. Real-world effectiveness of burosumab across age groups: X-linked hypophosphatemia (XLH) Disease Monitoring Program.. The Journal of clinical endocrinology and metabolism. 2026. DOI: 10.1210/clinem/dgag140.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.